 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
1 News |  |
| «1234» |
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers (clinicaltrials.gov) - Feb 24, 2020
P1, N=18, Recruiting, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers (clinicaltrials.gov) - Feb 24, 2020
P1, N=36, Recruiting, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers (clinicaltrials.gov) - Jan 18, 2020
P1, N=18, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 7, 2020
P1, N=36, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers (clinicaltrials.gov) - Nov 20, 2019
P1, N=36, Recruiting, Sponsor: CJ HealthCare Corporation
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants (clinicaltrials.gov) - Oct 20, 2019
P1, N=25, Completed, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT (clinicaltrials.gov) - Oct 15, 2019
P3, N=102, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers (clinicaltrials.gov) - Aug 26, 2019
P1, N=32, Completed, Sponsor: CJ HealthCare Corporation
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer (clinicaltrials.gov) - Aug 22, 2019
P3, N=306, Completed, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients (clinicaltrials.gov) - Aug 21, 2019
P3, N=350, Completed, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects (clinicaltrials.gov) - Aug 21, 2019
P1, N=12, Completed, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis (clinicaltrials.gov) - Jul 15, 2019
P3, N=318, Recruiting, Sponsor: CJ HealthCare Corporation
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects (clinicaltrials.gov) - Apr 3, 2019
P1, N=12, Recruiting, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects (clinicaltrials.gov) - Mar 4, 2019
P1, N=12, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants (clinicaltrials.gov) - Jan 24, 2019
P1, N=24, Recruiting, Sponsor: CJ HealthCare Corporation
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks (clinicaltrials.gov) - Nov 2, 2018
P3, N=290, Recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis (clinicaltrials.gov) - Nov 2, 2018
P3, N=260, Recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: Triple Therapy With Tegoprazan in H. Pylori Positive Patients (clinicaltrials.gov) - Aug 31, 2018
P3, N=284, Recruiting, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis (clinicaltrials.gov) - Aug 6, 2018
P3, N=260, Not yet recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks (clinicaltrials.gov) - Jul 19, 2018
P3, N=290, Not yet recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion, Trial completion date: A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability. (clinicaltrials.gov) - May 31, 2018
P1, N=38, Completed, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Aug 2018 --> May 2018
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: A Phase 1 Study of Tegoprazan on Healthy Male Volunteers (clinicaltrials.gov) - May 21, 2018
P1, N=44, Recruiting, Sponsor: CJ HealthCare Corporation
- |||||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Triple Therapy With Tegoprazan in H. Pylori Positive Patients (clinicaltrials.gov) - Apr 12, 2018
P3, N=284, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- ||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease (clinicaltrials.gov) - Apr 4, 2018
P3, N=324, Completed, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed | Trial completion date: Aug 2018 --> May 2018 Recruiting --> Completed
- |||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer (clinicaltrials.gov) - Apr 4, 2018
P3, N=306, Recruiting, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Jul 2018
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers (clinicaltrials.gov) - Mar 30, 2018
P1, N=16, Completed, Sponsor: CJ HealthCare Corporation
Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Jul 2018 Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability. (clinicaltrials.gov) - Mar 29, 2018
P1, N=38, Recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability. (clinicaltrials.gov) - Mar 29, 2018
P1, N=38, Recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers (clinicaltrials.gov) - Dec 18, 2017
P1, N=16, Recruiting, Sponsor: CJ HealthCare Corporation
- |||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients (clinicaltrials.gov) - Nov 27, 2017
P3, N=350, Recruiting, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients (clinicaltrials.gov) - Oct 23, 2017
P3, N=350, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- ||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - Sep 12, 2017
P3, N=302, Completed, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration (clinicaltrials.gov) - May 12, 2017
P1, N=60, Completed, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Pharmacodynamic Properties of CJ-12420 on Evening Dosing (clinicaltrials.gov) - Feb 6, 2017
P1, N=24, Completed, Sponsor: CJ HealthCare Corporation
- ||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration (clinicaltrials.gov) - Jan 5, 2017
P1, N=60, Recruiting, Sponsor: CJ HealthCare Corporation
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration (clinicaltrials.gov) - Jan 3, 2017
P1, N=16, Completed, Sponsor: CJ HealthCare Corporation
- |||||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - Dec 30, 2016
P3, N=300, Recruiting, Sponsor: CJ HealthCare Corporation
- |||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial primary completion date: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease (clinicaltrials.gov) - Dec 29, 2016
P3, N=324, Recruiting, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Trial primary completion date: Sep 2016 --> Jun 2017
- |||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open, Trial primary completion date: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer (clinicaltrials.gov) - Dec 28, 2016
P3, N=306, Recruiting, Sponsor: CJ HealthCare Corporation
Trial primary completion date: Sep 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Trial primary completion date: May 2017 --> Dec 2017
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects (clinicaltrials.gov) - Dec 15, 2016
P1, N=24, Completed, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting | Trial primary completion date: May 2017 --> Dec 2017 Active, not recruiting --> Completed
- ||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - Dec 15, 2016
P3, N=280, Completed, Sponsor: CJ HealthCare Corporation
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer (clinicaltrials.gov) - May 4, 2016
P3, N=306, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- |||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Enrollment open: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease (clinicaltrials.gov) - Apr 21, 2016
P3, N=324, Recruiting, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease (clinicaltrials.gov) - Sep 22, 2015
P3, N=324, Not yet recruiting, Sponsor: CJ HealthCare Corporation
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P3 trial: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - May 29, 2015
P3, N=280, Recruiting, Sponsor: CJ HealthCare Corporation
- K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - Aug 8, 2014
P2, N=206, Completed, Sponsor: CJ HealthCare Corporation
Not yet recruiting --> Recruiting Recruiting --> Completed
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects (clinicaltrials.gov) - Jan 30, 2014
P1, N=24, Active, not recruiting, Sponsor: CJ Cheiljedang Corporation
- ||||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P2 trial: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - Jan 5, 2014
P2, N=200, Recruiting, Sponsor: CJ Cheiljedang Corporation
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
New P1 trial: Food-Effect on PK and PD of Single Oral Dose of CJ-12420 in Healthy Male Subjects (clinicaltrials.gov) - Apr 10, 2013
P1, N=24, Completed, Sponsor: CJ Cheiljedang Corporation
- ||| K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects (clinicaltrials.gov) - Apr 8, 2013
P1, N=59, Completed, Sponsor: CJ Cheiljedang Corporation
Recruiting --> Completed Recruiting --> Completed